At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 50 target
Drug / intervention
Asciminibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
In Brief
A Phase 2 clinical trial evaluating Asciminib for Chronic Myeloid Leukemia. Currently recruiting, targeting 50 participants across 1 site.
Detailed Summary
To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Myeloid Leukemia
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2Recruiting
202420252026202720282029203020312032203320342035
Enrollment StartJan 2024
First PostedFeb 2024
TodayJul 2026
Primary CompletionJul 2033
Study CompletionJul 2035
First PostedFeb 1, 2024
Enrollment StartJan 31, 2024
Primary CompletionJul 1, 2033
Study CompletionJul 1, 2035
TodayJul 1, 2026
Enrollment to primary: 9.4 yearsPosted 2.4 years agoPrimary completion in 7 years
Arms & Interventions
Treatment with Asciminibexperimental
Participants will take tablets of asciminib by mouth every day on this study. Participants should take it at least 1 hour before and 2 hours after eating. The tablets should be swallowed whole, not crushed.
Drug: Asciminib
Interventions
Asciminibdrug
Given by PO